Compare Stanley Black & Decker, Inc. (SWK) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stanley Black & Decker, Inc. vs TG Therapeutics Inc — how do they compare? Stanley Black & Decker, Inc. trades at $87.62 (market cap $13.60B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Stanley Black & Decker, Inc. is the larger of the two by market cap, and Stanley Black & Decker, Inc. pays a 3.79% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SWK | TGTX | |
|---|---|---|
Market Cap | $13.60B | $8.26B |
52-Week High | $94.12 | $59.06 |
52-Week Low | $62.12 | $26.39 |
Enterprise Value | $19.77B | $8.50B |
Dividend Yield | 3.79% | — |
Sector | — | Health |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
